Background and aims: To prevent bacterial adherence and translocation, the colonic mucosa is covered by a protecting mucus layer and the epithelium synthesizes antimicrobial peptides. The present qualitative study investigated the contents and interaction of these peptides in and with rectal mucus. Methods: Rectal mucus extracts were analyzed for antimicrobial activity and screened with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Dot blot and immunohistochemistry for antimicrobial peptides. In addition, binding of AMPs to mucins was investigated by Western blot and enzyme-linked lectin assays. Results: In functional tests the mucus layer exhibited a strong antimicrobial activity. We detected 11 antimicrobial peptides in mucus extracts from healthy persons including the defensins HBD-1 and -3, the cathelicidin LL-37, ubiquitin, lysozyme, histones, high mobility group nucleosome-binding domain-containing protein 2, ubiquicidin and other ribosomal proteins. AMPs were bound by mucins but this was demonstrated to be reversible and inhibition of antibacterial activity was limited. Conclusion: These findings indicate that epithelial antimicrobial peptides are retained in the intestinal mucus layer without losing their efficacy. Thus, the mucus layer and its composition provide an attractive drug target to restore antimicrobial barrier function in intestinal diseases. © 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
Introduction
The human gastrointestinal tract is colonized by a variety of different microorganisms. 1 Containing 10 11-12 bacteria per gram of feces, especially the colon is confronted with a massive bacterial load. 2 To prevent bacterial adherence and translocation, the mucosa is protected against this potentially harmful environment by an efficient physical and chemical barrier. This complex defense system comprises numerous innate protective mechanisms, including the production of a large variety of antimicrobial peptides (AMPs) and the intestinal mucus layer. 1, 3 AMPs are used as a first line of immune defense by many organisms including plants, insects, bacteria and vertebrates. 4 Collectively, their antimicrobial spectrum reaches from killing of bacteria and some parasites to antifungal and antiviral activities. 5 The two most important families of AMPs in mammals are the defensins and the cathelicidins. 6 Human defensins are subdivided into two groups, α-and β-defensins, that differ in the length of the peptide segments between 6 conserved cysteine residues and their disulfidebonding pattern. 2 They are small cationic peptides with a molecular weight of 3-5 kDa. 7 Defensins are either produced constitutively, like the human β-defensin-1 (HBD-1) and the Paneth cell α-defensins, or they are inducible by proinflammatory stimuli and microbes or their products, like the human β-defensins HBD-2 and HBD-3. [8] [9] [10] [11] [12] The only cathelicidin identified in humans is called LL-37/ hCAP-18. 6 It is expressed by neutrophils, keratinocytes and epithelial cells including the colon and possesses a broad spectrum of activity against Gram-positive bacteria, Gramnegative bacteria and Candida albicans. 2 Other proteins with reported antibacterial activity are histones, ribosomal proteins and enzymes like lysozyme and phospholipase A 2 . 13, 14 In the human colon, a complex mixture of antimicrobial peptides is involved in the mucosal defense. In addition to the constitutively expressed β-defensin HBD-1, the cathelicidin LL-37, the inducible β-defensins HBD2-4, and the α-defensins HNP1-3, antimicrobially active members of the histone family, phospholipase A 2 , an eosinophil cationic protein and the ribosomal proteins L30, L39, S19 and S30 (ubiquicidin) have been already identified in the colonic mucosa. [15] [16] [17] [18] In addition to these directly active antimicrobial defense mechanisms, the intestinal mucosa is also protected by the intestinal mucus layer. This layer is a hydrated polymeric gel covering the mucosal surface. It protects the epithelium against mechanic disruption, toxins, enzymes and microorganisms and also has a lubricating function facilitating the passage of luminal contents. 19, 20 The colonic mucus layer consists of two parts -a normally sterile inner layer firmly attached to the epithelium and a loosely adherent outer layer colonized by bacteria. 21 Large glycoproteins belonging to the family of the secreted mucins are the major structural components of this protective gel. In the human gastrointestinal tract and associated tissues, the gel-forming secreted mucins MUC2, MUC5AC, MUC5B, MUC6 and MUC19 are expressed. 22 MUC2 is the predominant gel-forming mucin in the human colon. 3, 23 Its major importance for the maintenance of an intact mucus layer has been shown in MUC2 −/− mice that spontaneously developed colitis. 24 The carbohydrate structures of colonic mucins carry sulfate-and sialic acid residues, giving the mucins a highly negative charge. 25, 26 Owing to this negative charge and the viscoelastic net-like composition of mucus, the cationic positively charged AMPs might be retained in the large intestinal mucus layer. In the mouse small intestine it was recently suggested that indeed the secreted antimicrobial activity localizes to the mucus surface layer. 27 In this study, we tested the hypothesis of the mucus layer as a reservoir for antimicrobial components in the human large intestine.
Material and methods

Patients and sample preparation
Rectal mucus samples were collected during routine endoscopies at the Robert-Bosch-Hospital (Stuttgart) using sterile cytology brushes. Patients suffering from inflammatory bowel diseases or other rectal pathology were excluded. In addition, surgical resections of colonic tissue from patients with colon carcinoma were obtained from the Department of Surgery at our hospital.
Proteins from mucus samples were extracted by incubation in 60% acetonitrile containing 1% trifluoroacetic acid (TFA) according to Meyer-Hoffert et al. 27 with slight modifications. Subsequently, samples were centrifuged for 10 min at 8000 g and the supernatants were lyophilized. The pellets were re-dissolved in 10% ethanol and protease inhibitors were added. For subsequent experiments either this total protein extract was used or it was further fractionated by reversed-phase high-performance liquid chromatography (RP-HPLC) on an Agilent 1200 series system using a Zorbax 300SB-C18 column (4.6 × 150 mm, 3.5 μm, Agilent Technologies, Waldbronn, Germany) and a water/ acetonitrile gradient (solvent A: 0.18% TFA/H 2 0, solvent B: 0.15% TFA/acetonitrile). Fractions of 1.5 ml were collected, lyophilized and re-suspended in 0.01% acetic acid.
Antimicrobial assays
The antimicrobial activity of total mucus extracts from 6 control persons was assessed using a flow cytometric assay. 28 Briefly, suspensions of Escherichia coli ATCC 25922, Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 25923, Bacteroides fragilis ATCC 25285 and the clinical isolate Candida albicans 526 were grown in Schaedler Broth (diluted 1:6 with sterile water) at 37°C over night, B. fragilis in an anaerobic jar with Anaero Gen (Oxoid, Wesel, Germany). Subsequently, 1.5 × 10 6 bacteria/ml in 1:6 diluted Schaedler Broth were incubated with 50 μg total protein of each total mucus extract in a final volume of 100 μl for 120 min at 37°C. Bacteria incubated with 5 μl 0.01% acetic acid and 5 μg/100 μl recombinant HBD-3 (PeptaNova, Sandhausen, Germany) served as negative and positive controls respectively. Afterwards, the samples were incubated with 1 μg/ml bis-(1,3-dibutylbarbituric acid) trimethine oxonol [DiBAC 4 (3) ] (Invitrogen/Life Technologies).
For investigation of HPLC fractionated extracts E. coli ATCC 25922 and S. aureus ATCC 25923 were incubated with 6 μl extract as described above. e653 Human colonic mucus is a reservoir for antimicrobial peptides
Separation of free and mucin bound AMPs
AMPs bound to mucins were separated from free AMPs by a 100 kDa cut-off centrifugation using Roti-Spin Mini-centrifugal devices (Roth, Karlsruhe, Germany). Subsequently, the high molecular weight fraction was incubated with a suspension of E. coli ATCC 25922. The viability of bacteria was assessed with fluorescence microscopy by the simultaneous staining with SYTO 9 and propidium iodide (BacLight Bacterial viability Kit, Invitrogen/Life Technologies, Carlsbad, CA, USA). Intact bacteria showed green fluorescence, and dead bacteria red fluorescence. Additionally, antimicrobial activity of 5 μl of both fractions as well as the total protein extracts was analyzed by flow cytometry against E. coli ATCC 25922.
Flow cytometry
The percentage of dead fluorescent bacteria was determined using a FACSCalibur flow cytometer (Becton Dickinson, Sparks, MD, USA). Total extracts were tested for antimicrobial activity with all bacterial strains, HPLC-fractions with E. coli ATCC 25922 and S. aureus ATCC 25923. Percentages of depolarized bacteria in solvent controls (range 4.6-8.9) were subtracted from total values of depolarized bacteria in every experiment.
Additionally, to assess inhibition of antimicrobial activity by mucins, E. coli ATCC 25922 was incubated with 5 μg LL-37 (Innovagen, Lund, Sweden) or 5 μg HBD-3 (PeptaNova, Sandhausen, Germany) in the presence of 0, 30, 60, 90 or 120 μg/100 μl total protein of the human mucus samples or mucin from porcine stomach (Sigma-Aldrich, Steinheim, Germany). Antimicrobial activity was measured by flow cytometry.
Characterization and identification of HPLC fractions 2.3.1. Gel electrophoresis
After fractionation of total protein extracts by RP-HPLC 3 μl of NuPAGE LDS sample buffer (Invitrogen/Life Technologies) were added to 9 μl of each fraction. The samples were electrophoretically separated on 12% Bis-Tris gels (Invitrogen/ Life Technologies) at 100 V for 90 min and the gels were stained with Coomassie brilliant blue.
Additionally, in vitro-dimer formation of HBD-1 and HBD-2 was analyzed by Coomassie-staining of protein gels. Suspensions of the recombinant peptides (0.5 mg/ml in 0.01% acetic acid; PeptaNova) were incubated overnight. The next day, 4 μl Millipore-H 2 0 and 3 μl of NuPAGE LDS sample buffer were added to 5 μl of each peptide solution and the following electrophoresis and staining were carried out as described above. 200 ng of monomeric HBD-1 and HBD-2 (dissolved in 2 μl 0.01% acetic acid) were used as peptide standards.
Dot blot analysis
For systematic determination of antimicrobial peptides by Dot blot, brushes of 25 control individuals (14 females with an average age of 69 years (range 37-95) and 11 males with an average age of 59 years (range 42-74)) were analyzed.
1.5 μl of whole mucus extracts were applied on a nitrocellulose membrane (Whatman, Dassel, Germany). The membrane was air-dried, blocked in 5% skimmed milk powder (Sigma-Aldrich (Fluka), Buchs, Switzerland) in TBST (25 mM Tris-Base, 140 mM NaCl, 2.7 mM KCl, 0.1% Tween 20, pH 7.4) for 1 h at room temperature and incubated with the respective primary antibody diluted in 5% skimmed milk powder in TBST at 4°C over night (HBD-1 antibody: PeproTech, Hamburg, Germany, dilution 1:5000; LL-37: Santa Cruz, Heidelberg, Germany, dilution 1:2000; HBD-3: Santa Cruz, Heidelberg, Germany, dilution 1:2000; Histone H2A: BioVision, Mountain View, CA, USA, dilution 1:1000; Histone H2B: Abcam, Cambridge, United Kingdom, dilution 1:500; ubiquitin: antibodiesonline, Aachen, Germany, dilution 1:1000; lysozyme: Abcam, Cambridge, United Kingdom, dilution 1:1000). After washing with TBST, the membrane was incubated with the horseradish peroxidase (HRP)-conjugated-secondary antibody (Jackson ImmunoResearch Laboratories, Newmarket, Suffolk, UK, 1:5000 in 5% skimmed milk powder in TBST) for 1 h at room temperature. After a second washing step, the reaction was developed using the SuperSignal West Dura Extended Duration Substrate of Pierce (Rockford, IL) and documented with a Las1000 cooled CCD-Camera system (Fujifilm, Tokio, Japan).
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS)
0.75 μl of each HPLC-fraction were co-crystallized with 0.75 μl of a THAP (2′,4′,6′-trihydroxyacetophenone)/DAHC (Diammonium hydrogen citrate)-matrix containing 11 mg ml 
Immunohistochemistry
For immunohistochemistry, surgical resections of colonic tissue were Carnoy-fixed and paraffin-embedded. Primary antibodies against HBD-1 and LL-37 were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). 3 μm thick sections of Carnoy-fixed, paraffin-embedded sections of colonic tissue were heated for 20 min in a steamer (pH 6) to retrieve the antigens and incubated for 30 min with the primary antibodies (1:50 diluted in Dako REAL™ Antibody Diluent; Dako, Hamburg, Germany). After incubation with a dextran-bound HRP-coupled secondary antibody, the reaction was visualized using the substrate diaminobenzidine (Dako REAL™ EnVision™ Detection system, Peroxidase/DAB +, rabbit/mouse). Immunohistochemistry was carried out on a Dako Autostainer Plus 3.
Defensin/mucin binding-experiments 2.5.1. Enzyme-linked lectin assay (ELLA)
According to Felgentreff et al. 29 , 96-Well MaxiSorp Immuno-Plates (Nunc, Roskilde, Denmark) were coated with 5 μg recombinant HBD-1, HBD-2 or HBD-3 (PeptaNova) or LL-37 (Innovagen) dissolved in 100 μl coating buffer (50 mM NaHCO 3 /Na 2 CO 3 , pH 9.6) per well at 4°C over night. 100 μl coating buffer alone was used as a negative control. The next day, each well was washed 3 times with phosphate buffered saline (PBS) containing 1% Tween 20. Afterwards, the wells were incubated with PBS containing 1% albumin (1 h) and washed again. Next, mucin from porcine stomach (Sigma-Aldrich) dissolved in 1% albumin/PBS was added in increasing concentrations ranging from 0 to 75 μg/100 μl mucin per well. Mucin dilutions applied to defensin-uncoated wells were used as reference values. Following incubation at 4°C over night, the wells were washed and 50 ng biotinylated lectin was added for 2 h at room temperature. Subsequently, peroxidase-coupled streptavidin was loaded to each well and incubated for 30 min at room temperature. 3,3′,5,5′-Tetramethylbenzidine (TMB) (Dako) was added and after 10 min the reaction was stopped with 1 N H 2 SO 4 . Absorption was measured using a Wallac Victor™ 1420 Multilable Counter (Waltham, MA, USA) at a wavelength of 490 nm.
Western blot
To investigate binding of HBD-1, HBD-2, HBD-3 and LL-37 to the mucin MUC2, 100 ng of the respective peptide were incubated with mucus extracts of controls and a patient with ulcerative colitis at 37°C for 20 min. Free peptide served as standard. Electrophoresis was carried out for 60 min at 150 V, using a 3-8% Tris-Acetate gel (Invitrogen/Life Technologies). Proteins were wet blotted to a nitrocellulose membrane (Whatman; 25 V, 100 mA, 1 h), free binding sites of the membrane were blocked by incubation with 5% skimmed milk powder in TBST for 1 h at room temperature and the Western-blotting procedure was continued as described previously. 30 The primary antibodies against the antimicrobial peptides (anti-HBD-1: Pepro Tech 1:5000; anti-HBD-2, anti-HBD-3, anti-LL-37: Santa Cruz 1:2000) and the HRP-coupled secondary antibody (goat anti-rabbit; Jackson Immuno Research Laboratories 1:5000) were diluted in 5% skimmed milk powder in TBST.
To test whether HBD-2 bound to the mucin MUC2, a second Western blot was performed. For this experiment the experimental conditions were identical to the first Western blot, with the exception that the blot was developed using an antibody detecting MUC2 (dilution 1:1000; antibodiesonline).
Binding of mucus-associated LL-37 to bacterial membranes
Mucus from cytology brushes was smeared on microscope slides and covered with a suspension of E. coli ATCC 25922. After 60 min incubation, the bacterial cells were removed by rinsing. This bacterial suspension was incubated with a biotinylated antibody against LL-37 (Innovagen) and after 10 min incubation time, streptavidin (Becton Dickinson) was added and further incubated for 10 min. For simultaneous assessment of bacterial killing, 1 μg/ml DiBAC 4 (3) (Invitrogen) was added for viability testing. Green fluorescence 1 and red fluorescence 2 were measured with a FACSCalibur flow cytometer (Becton Dickinson).
Ethical considerations
All patients gave their written informed consent and the study was approved by the ethical committee of the University of Tübingen.
Results
Mucus displays strong antimicrobial activity
First, β-actin Dot blots were performed to exclude a potential contamination of mucus samples with epithelial cells. Protein extracts of colonic resection specimens were used as positive control. Due to the absence of β-actin in mucus extracts (Fig. 1a) it can be assumed that the antimicrobial effect of mucus extracts is not attributable to a contamination of mucus with cells or cellular debris.
Next, we assessed the antimicrobial activity of peptides bound in mucus extracts against E. coli ATCC 25922 by fluorescence microscopy. Large molecular weight (mucinbound) antimicrobial components were separated from free antimicrobial peptides by a 100 kDa cut-off centrifugation. Subsequently, the high molecular weight fraction was applied to microscope slides and incubated with a suspension of E. coli ATCC 25922. Bacterial killing was visualized using the live-dead staining with SYTO 9 and propidium iodide. In the E. coli control suspension, not incubated with the high molecular weight fraction of mucus, bacteria were alive and showed a green fluorescence (Fig. 1b) whereas the E. coli population incubated with the high molecular weight fraction of mucus contained a high proportion of dead red-fluorescent bacteria (Fig. 1c) .
To obtain a broader overview of the antimicrobial spectrum of mucus extracts, the microbicidal effect of whole mucus extract from 6 controls was subsequently investigated against different Gram-positive bacteria (S. aureus ATCC 25923, E. faecalis ATCC 29212), Gram-negative bacteria (B. fragilis ATCC 25285, E. coli ATCC 25922) and the yeast C. albicans 526 using a flow cytometric assay with the membrane potentialsensitive dye DiBAC 4 (3). Fig. 1d illustrates the antimicrobial activity of mucus samples. All mucus extracts displayed strong antimicrobial activity against all bacterial strains tested as well as against C. albicans. In the solvent suspension controls we found only 4.6-8.9% depolarized microorganisms.
Mucus contains a mixture of antimicrobial peptides
For further analyses we separated mucus extracts by reversedphase high-performance liquid chromatography (RP-HPLC) (Fig. 2a) and investigated the bactericidal activity of the obtained fractions against E. coli ATCC 25922 and S. aureus ATCC 25923 (Fig. 2b) by flow cytometry. Several HPLCfractions displayed antimicrobial activity against both bacterial strains. The bactericidal effect against both strains varied considerably between the HPLC-fractions. The antimicrobial effect of the HPLC-fractions against the Gram-positive strain S. aureus ATCC 25923 seemed to be more pronounced than against the Gram-negative strain E. coli ATCC 25922.
To get an overview of the physiological peptide profile in intestinal mucus and to further characterize the fractionated extracts, HPLC-fractions were electrophoretically separated and stained with Coomassie brilliant blue (Fig. 3a) . Furthermore, HPLC-fractions of mucus extracts were screened for peptides and proteins with known antimicrobial activity using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Additionally, several antimicrobial peptides/proteins were identified in whole mucus extracts by Dot blot analyses ( Table 1) .
The constitutively expressed β-defensin HBD-1 and the cathelicidin LL-37 could be identified by Dot blot in 11 (44.0%) and 14 (56.0%) out of 25 control persons respectively (Table 1 and Fig. 3b/c) . The presence of HBD-1 and LL-37 in mucus was also confirmed by immunohistochemical staining of Carnoy-fixed colonic mucosal tissue (Fig. 3d/e) . The protein mass of HBD-1 or LL-37 in MALDI-TOF-MS was found only sporadically; rather we detected a protein mass indicating HBD-1-dimers (Fig. 4a) . This assumption of a dimer formation was supported in protein gels showing in vitro formation of HBD-1-and HBD-2-dimers (Fig. 4b) .
Additional proteins with known antimicrobial activity that could be identified in mucus extracts of control persons by Dot blot were the histones H2A and H2B (H2A and H2B 32.0% positive samples). The presence of H2A and H2B in mucus was also confirmed by mass spectrometry (H2A with 14.019/ 14.020 kDa in HPLC-fraction 17 and H2B with 13.799 kDa in HPLC-fraction 16; Fig. 5 ). Ubiquitin was detected in 36.0% of the samples by Dot blot analyses. By MALDI-TOF-MS, we detected a mass corresponding to ubiquitin in HPLC-fractions 10 and 11 (8.561 and 8.569 kDa; Fig. 5 ). Furthermore, lysozyme and HBD-3 were identified in the whole mucus extracts by Dot blot (Table 1) . Finally, we found by HPLC followed by MALDI-TOF-MS in mucus extracts some additional known antibacterial peptides/proteins with nearly identical measured versus expected masses (Table 2) . From the family of ribosomal proteins, we detected L30 and L39 with approximately 12.8 kDa and 6.3 kDa by MALDI-TOF-MS. Additionally, in fractions 4 and 7 an antimicrobial peptide of 6.649 kDa was identified as ubiquicidin and fraction 5 Figure 1 Antimicrobial activity of rectal mucus extracts. a) Mucus extracts were free of cell debris as confirmed by negative Dot blot for β-actin. Protein extracts of colonic mucosa samples were used as positive control (1.0 μl protein extract). b) and c) Detection of antimicrobial activity in mucus against E. coli ATCC 25922 with BacLight. The antimicrobial activity was assessed using fluorescence microscopy with the two nucleic acid stains SYTO 9 (living bacteria fluoresce green) and propidium iodide (dead bacteria fluoresce red). In the E. coli control not incubated with mucus, bacteria are alive (b) whereas the E. coli population incubated with mucus extract contains predominantly dead bacteria with a red fluorescence (c). Representative staining for a total of 3 experiments. d) Flow cytometric viability assay with DiBAC 4 (3). Antimicrobial activity of mucus extracts containing 50 μg/100 μl protein extract from 6 individuals against E. coli ATCC 25922, S. aureus ATCC 25923, E. faecalis ATCC 29212, B. fragilis ATCC 25285 and C. albicans 526, (means + SEM). contained a member of the high mobility group-superfamily, the high mobility group nucleosome-binding domain-containing protein 2 (HMGN2; Fig. 5 ). However, there was significant inter-individual variation with respect to the presence of these peptides in mucus.
Mucus binds defensins and cathelicidin
First, we analyzed whether AMPs are associated with high molecular weight components in mucus extracts. Following 100 kDa cut-off centrifugation, the antimicrobial activity of separated extracts was mainly located in the high molecular weight fraction (Fig. 6a) . Thus, only a small portion of antimicrobially active components in mucus extracts was present in free form, whereas the major part was bound to high molecular weight molecules, probably mucins.
In the next step, we wanted to examine whether high molecular weight, negatively charged mucins are actually involved in the binding of AMPs in mucus. In Western blot experiments, the binding of the defensins HBD-1, HBD-2 and HBD-3 and the cathelicidin LL-37 to the mucin MUC2 was demonstrated. The protein gels in Fig. 6b were loaded with samples in the same way but gels 1 and 2 were developed with an antibody against HBD-2 whereas in gel 3 an antibody detecting the mucin MUC2 was used. According to its low molecular weight of 4.328 kDa free recombinant HBD-2 migrated to the bottom of the gel whereas HBD-2 preincubated with mucus was detected at a location characteristic for high molecular weight mucins. As demonstrated with the third Western blot, this protein-band actually contained the mucin MUC2. Mucus not incubated with HBD-2 showed no reaction with the HBD-2 antibody if it was from persons without colonic inflammation. In contrast, in mucus from patients with active ulcerative colitis we detected endogenous HBD-2.
Binding of AMPs to mucins was also demonstrated by enzyme-linked lectin assays. The results of these experiments showed that the cationic antimicrobial peptides HBD-1, HBD-2 and HBD-3 and the cathelicidin LL-37 bound mucins in a concentration dependent manner (Fig. 6c). 
Binding of cationic antimicrobial peptides to mucus is reversible
Since mucin binding may be irreversible and might block antimicrobial peptide activity, we studied the effect of binding on AMP function. With a flow cytometric test we showed that the mucus-bound antimicrobial peptide LL-37 partitioned into the bacterial membrane during incubation with a suspension of E. coli ATCC 25922 (Fig. 7a) . Staining with the membrane potential-sensitive dye DiBAC 4 (3) showed that N 30% of the depolarized bacteria in a suspension were killed by LL-37 from mucus. The remaining percentage of bacteria apparently was depolarized by other antimicrobial components in mucus, probably defensins and other antimicrobial peptides (Fig. 7b) . With an antibody against LL-37 the antimicrobial activity of this peptide in the mucus could be blocked to almost half of the primary activity (Fig. 7c/d) . Therefore, binding of AMPs in mucus seems to be reversible and the functional activity is maintained.
This conclusion was further supported by a complementary flow cytometric experiment, in which increasing concentrations of mucin from porcine stomach or increasing protein concentrations of human mucus extracts were incubated with the antimicrobial peptides LL-37 or HBD-3. Incubation of LL-37 with porcine gastric mucin resulted in a limited decrease of bacterial killing from a control 77% without mucin to 51% with 60 μg/ml mucin, higher mucin concentrations exerted no additional inhibition of LL-37 activity. Similarly, 30 μg/ml of human mucus extracts inhibited the activity to 67%, with increasing mucus concentrations the antimicrobial activity remained in the range of 60% depolarized bacteria. Finally, porcine mucus decreased the antimicrobial activity of HBD-3 from 77 to 46%, but HBD-3 was only marginally inhibited by mucus extracts (78% bacterial killing without mucus, 73% with 120 μg mucus extract) (Fig. 8) .
Discussion
The enormous luminal surface of the human intestinal tract is constantly in close contact with a dense bacterial flora.
Therefore, maintenance of an intact and efficient mucosal barrier is essential for survival of the host. For this purpose the intestinal mucosa possesses diverse defense mechanisms, including the synthesis of a complex array of antimicrobial peptides and, in addition, a protecting mucus layer covering the mucosal surface to block bacteria from attacking the epithelium. This is probably of particular importance in the colon with its immense bacterial load but a similar shield is protecting the stomach and small intestine as well. 8, 12, 17, 31, 32 The principal aim of the present study was to investigate qualitatively the role of the mucus layer in the maintenance of an effective antimicrobial defense in the healthy large intestine. Protein extracts of rectal mucus samples were analyzed for their antimicrobial activity and screened for AMPs. The binding of AMPs in mucus and to mucins as well as its reversibility was also investigated. In different functional tests, we could show that the rectal mucus layer exhibits a strong antimicrobial activity. The bactericidal effect of mucus extracts against E. coli ATCC 25922 was clearly illustrated by fluorescence microscopy. Furthermore, the antimicrobial activity of whole mucus extracts against different Gram-positive (S. aureus ATCC 25923, E. faecalis ATCC 29212) and Gram-negative bacterial strains (B. fragilis ATCC 25285, E. coli ATCC 25922) as well as the yeast C. albicans 526 was detailed using a flow cytometric assay. Additionally, the antimicrobial effect of RP-HPLC-fractions of mucus extracts against E. coli ATCC 25922 and S. aureus ATCC 25923 was measured by flow cytometry. These results are in good accordance with the data of Meyer-Hoffert et al., who analyzed the spatial distribution of AMPs in different compartments of the murine small intestine and found that the mucus layer had a strong antibacterial activity against commensal and pathogenic bacteria. In their study the composition of the AMPs in the mucus layer resembled the spectrum in whole small intestinal or crypt preparations and the authors concluded that in the mouse small intestine epithelial AMPs are retained in the mucus layer to sustain high local peptide concentrations. 27 By Dot blot and MALDI-TOF-MS analyses we searched for antimicrobial peptides/proteins in whole and fractionated mucus extracts respectively. Besides the constitutively expressed β-defensin HBD-1 and the cathelicidin LL-37, we identified ubiquitin, lysozyme, HBD-3 and two members of the histone family (histones H2A and H2B) with known antibacterial functions 14, 17, 18, 33, 34 by Dot blot analyses in whole mucus extracts. Antimicrobial properties of ubiquitin have been reported in the literature 35, 36 and lysozyme is involved in the defense of several mucosal surfaces, including nasal secretions, or in the intestine. [37] [38] [39] Ubiquitin, H2A and H2B were also detected by MALDI-TOF-MS in some HPLC fractions of mucus extracts. Furthermore, masses corresponding to HMGN2 and the ribosomal proteins L30, L39 and ubiquicidin (ribosomal protein S30), also proteins with reported antibacterial activity, were detected in several HPLC-fractions by MALDI-TOF-MS. 17, 18, 40, 41 Additionally, the presence of HBD-1 and LL-37 in mucus could be confirmed by immunostaining of Carnoy-fixed colonic tissue. By MALDI-TOF-MS, masses corresponding to HBD-1 and LL-37 were detected only sporadically and with low intensity. One possible reason for this is a dimer or oligomer formation of the peptides, an assumption that was substantiated by Coomassie-staining of protein gels showing an in vitro-dimer formation of AMPs. Dimer formation of AMPs has already been reported in literature. 42 Another possibility is that HBD-1 and LL-37 were bound in mucus extracts in larger protein complexes. This is supported by the results of Western blot experiments with mucus extracts (data not shown). In these experiments HBD-1 and LL-37 were not detected in the range of their actual molecular weight of 3.929 kDa for HBD-1 and 4.493 kDa for LL-37 respectively but rather in the upper part of the gels corresponding to higher molecular weights. The peptides were apparently present in mucus as part of larger protein complexes with as yet unknown proteins.
Notably, in two previous investigations the spectrum of AMPs in the non-inflamed colonic mucosa was examined and ubiquicidin, histone H2B, histone H1.5, eosinophil cationic protein, phospholipase A 2 , LL-37, HNP1-3, HBD-1 and ribosomal proteins S19, L30 and L39 were identified as antimicrobial active constituents of mucosal protein extracts. 17, 18 In the present study, we recovered several of these peptides/proteins (ubiquicidin, histone H2B, HBD-1, LL-37, ribosomal proteins L30 and L39) in large intestinal mucus, indicating that AMPs are synthesized in the mucosa and retained in the mucus layer. Recently Schröder et al. could show that the antimicrobial activity of HBD-1 is activated by thioredoxin and that thioredoxin and reduced HBD-1 are localized in the colonic mucus. 43, 44 Binding of cationic AMPs to mucins was evident in a flow cytometric viability test which showed that the antimicrobial activity of mucus extracts was mainly recovered in the high molecular weight fraction, containing mucins and bound antimicrobial peptides. By Western blot analyses and enzyme-linked lectin assays we confirmed binding of the β-defensins and the cathelicidin LL-37 to mucins. This binding is most likely due to electrostatic interactions because large intestinal mucins are negatively charged whereas cationic AMPs are positively charged. An electrostatic interaction of the cationic AMP LL-37 with mucins has already been shown by Felgentreff et al. 29 and Bucki et al. 45 .
As we confirmed by flow cytometry with the cathelicidin LL-37 and the Gram-negative bacterial strain E. coli ATCC 25922, binding of cationic AMPs in mucus is reversible. Mucus-bound LL-37 was released from mucus upon incubation with bacteria, partitioned to the membrane of E. coli ATCC 25922 and retained its killing potential as evident from the high percentage of dead fluorescent bacteria with LL-37 Figure 6 Binding of antimicrobial peptides to mucins. a) Flow cytometry. Separation of 300 μg total protein of mucus extracts in a fraction with low molecular weight components (b 100 kDa) and high molecular weight components (N 100 kDa) and subsequent detection of the antimicrobial activity against E. coli ATCC 25922. The antimicrobial activity is mainly localized in the high molecular weight fraction (two separate experiments). b) Western blot. Recombinant HBD-2, mucus extract from a control patient (left panel) or from a patient with UC (mid panel) native or preincubated with recombinant HBD-2. The blots were developed with an antibody directed against HBD-2. According to its low molecular weight free recombinant HBD-2 was detected at the bottom of the gel whereas recombinant HBD-2 preincubated with mucus stayed on top of the gel. Right panel: confirmation that the mucin MUC2 was involved in the binding of HBD-2. Recombinant peptide and mucus samples were loaded to a protein gel according to experiment 1, but the blot was developed with an antibody against MUC2. The MUC2-antibody detected protein-bands in the gel that were located in the same height as the protein-bands detected by the HBD-2-antibody in the first two Western blots. c) Enzyme-linked lectin assay. Microtiter plates were coated with the β-defensins HBD-1, HBD-2, HBD-3 and the cathelicidin LL-37. Subsequently, the plates were incubated with serial dilutions of porcine gastric mucin. After addition of a biotinylated mucin-binding lectin, the reaction was developed with a streptavidin-peroxidase conjugate and the substrate tetramethylbenzidine. The signal intensity measured at 490 nm increased continuously with increasing mucin concentrations because mucins bound in a concentration dependent fashion to the cationic antimicrobial peptides. Values represent means from two independent experiments + SEM.
integrated in their membrane. This proves that binding of LL-37 to mucus is, at least in part, reversible and that the antimicrobial activity of the peptide is maintained. These findings were confirmed by the results of a further flow cytometric analysis, showing that the antimicrobial activity of LL-37 or HBD-3 was not substantially diminished in the presence of mucus. A somewhat stronger inhibitory effect was observed in salivary mucus by Bucki et al. 45 and Felgentreff et al. 29 showed with mucin from porcine stomach that the electrostatic interaction of LL-37 with mucins induced an alpha-helical conformation of the peptide and modulated its antibacterial functions, also resulting in a decreased antimicrobial activity.
Since we isolated the whole mucus layer we could not distinguish whether the isolated antimicrobial peptides were bound in the inner or in the outer layer. The outer layer harbors commensal bacteria, in contrast to the inner layer, which is in principle devoid of microorganisms. 21, 46 It seems plausible that epithelial secretion leads to a higher peptide concentration in the inner layer whereas commensals are invading from the lumen until they get killed.
In conclusion, this study shows that mucus serves as a reservoir for AMPs and helps to maintain the sterility of the healthy epithelium. A rapid diffusional loss of AMPs into the gut lumen is prevented without significant loss of functional antibacterial activity. Since modifications of defensins as well as other antibacterial peptides 1, 16, [47] [48] [49] and the mucus layer 30, 31, [50] [51] [52] [53] have been reported in inflammatory bowel disease (IBD) study of mucus in these diseases is warranted. This study laid the groundwork for further studies on quantitative and qualitative differences between normal mucus and that in inflammatory bowel disease. Figure 7 Reversibility of the binding of LL-37 in mucus. Integration of LL-37 from mucus in the membrane of E. coli ATCC 25922, incubated with a biotinylated antibody against LL-37 (a) and simultaneous staining with DiBAC 4 (3) (b). The y-axis depicts bacterial binding of LL-37, red fluorescence 2; x-axis depicts bacterial killing, green fluorescence 1. Quadrants were set corresponding to bacteria not incubated with LL-37. Antimicrobial activity of a control mucus sample against E. coli ATCC 25922 (c) and partial blocking of this bactericidal effect by prior incubation with an LL-37 antibody (d). Representative sample, experiment was performed in duplicate. DiBAC 4 (3), bis-(1,3-dibutylbarbituric acid) trimethine oxonol.
